AAAAAA

   
Results: 1-25 | 26-27
Results: 1-25/27
Rhodococcus equi pneumonia in a patient with human immunodeficiency virus:Case report and review
Authors: Kwa, AL Tam, VH Rybak, MJ
Citation: Al. Kwa et al., Rhodococcus equi pneumonia in a patient with human immunodeficiency virus:Case report and review, PHARMACOTHE, 21(8), 2001, pp. 998-1002
Comparison of length of hospital stay for patients with known or suspectedmethicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial
Authors: Li, ZM Willke, RJ Pinto, LA Rittenhouse, BE Rybak, MJ Pleil, AM Crouch, CW Hafkin, B Glick, HA
Citation: Zm. Li et al., Comparison of length of hospital stay for patients with known or suspectedmethicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: A randomized, multicenter trial, PHARMACOTHE, 21(3), 2001, pp. 263-274
New milestones achieved in fluoroquinolone safety
Authors: Tillotson, GS Rybak, MJ
Citation: Gs. Tillotson et Mj. Rybak, New milestones achieved in fluoroquinolone safety, PHARMACOTHE, 21(3), 2001, pp. 358-360
Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam
Authors: Jellison, TK McKinnon, PS Rybak, MJ
Citation: Tk. Jellison et al., Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam, PHARMACOTHE, 21(2), 2001, pp. 142-148
Activities of newer fluoroquinolones against ciprofloxacin resistant Streptococcus pneumoniae
Authors: Coyle, EA Kaatz, GW Rybak, MJ
Citation: Ea. Coyle et al., Activities of newer fluoroquinolones against ciprofloxacin resistant Streptococcus pneumoniae, ANTIM AG CH, 45(6), 2001, pp. 1654-1659
Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations
Authors: Akins, RL Rybak, MJ
Citation: Rl. Akins et Mj. Rybak, Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations, ANTIM AG CH, 45(2), 2001, pp. 454-459
Emergence of methicillin-resistant Staphylococcus aureus with intermediateglycopeptide resistance - Clinical significance and treatment options
Authors: Rybak, MJ Akins, RL
Citation: Mj. Rybak et Rl. Akins, Emergence of methicillin-resistant Staphylococcus aureus with intermediateglycopeptide resistance - Clinical significance and treatment options, DRUGS, 61(1), 2001, pp. 1-7
Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in anin vitro infection model
Authors: Houlihan, HH Stokes, DP Rybak, MJ
Citation: Hh. Houlihan et al., Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in anin vitro infection model, J ANTIMICRO, 46(1), 2000, pp. 79-86
Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: Case report and review
Authors: Tam, VH McKinnon, PS Levine, DP Brandel, SM Rybak, MJ
Citation: Vh. Tam et al., Once-daily aminoglycoside in the treatment of Enterococcus faecalis endocarditis: Case report and review, PHARMACOTHE, 20(9), 2000, pp. 1116-1119
Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function
Authors: Neuhauser, MM McKinnon, PS Hershberger, E Rybak, MJ
Citation: Mm. Neuhauser et al., Pharmacokinetics and pharmacodynamics of ceftizoxime in patients with dosages adjusted for renal function, PHARMACOTHE, 20(5), 2000, pp. 554-561
Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations
Authors: Hershberger, E Coyle, EA Kaatz, GW Zervos, MJ Rybak, MJ
Citation: E. Hershberger et al., Comparison of a rabbit model of bacterial endocarditis and an in vitro infection model with simulated endocardial vegetations, ANTIM AG CH, 44(7), 2000, pp. 1921-1924
In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model
Authors: Akins, RL Rybak, MJ
Citation: Rl. Akins et Mj. Rybak, In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model, ANTIM AG CH, 44(7), 2000, pp. 1925-1929
Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin-intermediate Staphylococcus aureus inan in vitro pharmacodynamic infection model
Authors: Aeschlimann, JR Hershberger, E Rybak, MJ
Citation: Jr. Aeschlimann et al., Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin-intermediate Staphylococcus aureus inan in vitro pharmacodynamic infection model, ANTIM AG CH, 44(5), 2000, pp. 1153-1158
In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains
Authors: Rybak, MJ Hershberger, E Moldovan, T Grucz, RG
Citation: Mj. Rybak et al., In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains, ANTIM AG CH, 44(4), 2000, pp. 1062-1066
Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model
Authors: Hershberger, E Rybak, MJ
Citation: E. Hershberger et Mj. Rybak, Activities of trovafloxacin, gatifloxacin, clinafloxacin, sparfloxacin, levofloxacin, and ciprofloxacin against penicillin-resistant Streptococcus pneumoniae in an in vitro infection model, ANTIM AG CH, 44(3), 2000, pp. 598-601
Activities of LY333328 and vancomycin administered alone or in combinationwith gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model
Authors: Aeschlimann, JR Allen, GP Hershberger, E Rybak, MJ
Citation: Jr. Aeschlimann et al., Activities of LY333328 and vancomycin administered alone or in combinationwith gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model, ANTIM AG CH, 44(11), 2000, pp. 2991-2998
Influence of platelets and platelet microbicidal protein susceptibility onthe fate of Staphylococcus aureus in an in vitro model of infective endocarditis
Authors: Mercier, RC Rybak, MJ Bayer, AS Yeaman, MR
Citation: Rc. Mercier et al., Influence of platelets and platelet microbicidal protein susceptibility onthe fate of Staphylococcus aureus in an in vitro model of infective endocarditis, INFEC IMMUN, 68(8), 2000, pp. 4699-4705
The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model
Authors: Aeschlimann, JR Kaatz, GW Rybak, MJ
Citation: Jr. Aeschlimann et al., The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model, J ANTIMICRO, 44(3), 1999, pp. 343-349
Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital
Authors: Weingarten, CM Rybak, MJ Jahns, BE Stevenson, JG Brown, WJ Levine, DP
Citation: Cm. Weingarten et al., Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital, PHARMACOTHE, 19(9), 1999, pp. 1080-1085
Outcome assessment of minimizing vancomycin monitoring and dosing adjustments (vol 19, pg 257, 1999)
Authors: Karam, CM McKinnon, PS Neuhauser, MM Rybak, MJ
Citation: Cm. Karam et al., Outcome assessment of minimizing vancomycin monitoring and dosing adjustments (vol 19, pg 257, 1999), PHARMACOTHE, 19(5), 1999, pp. 674-674
Outcome assessment of minimizing vancomycin monitoring and dosing adjustments
Authors: Karam, CM McKinnon, PS Neuhauser, MM Rybak, MJ
Citation: Cm. Karam et al., Outcome assessment of minimizing vancomycin monitoring and dosing adjustments, PHARMACOTHE, 19(3), 1999, pp. 257-266
Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside
Authors: Murry, KR McKinnon, PS Mitrzyk, B Rybak, MJ
Citation: Kr. Murry et al., Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside, PHARMACOTHE, 19(11), 1999, pp. 1252-1260
Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family
Authors: Foster, DR Rybak, MJ
Citation: Dr. Foster et Mj. Rybak, Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family, PHARMACOTHE, 19(10), 1999, pp. 1111-1117
Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcusaureus
Authors: Aeschlimann, JR Hershberger, E Rybak, MJ
Citation: Jr. Aeschlimann et al., Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcusaureus, ANTIM AG CH, 43(8), 1999, pp. 1914-1918
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
Authors: Rybak, MJ Abate, BJ Kang, SL Ruffing, MJ Lerner, SA Drusano, GL
Citation: Mj. Rybak et al., Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity, ANTIM AG CH, 43(7), 1999, pp. 1549-1555
Risultati: 1-25 | 26-27